BMRN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioMarin Pharmaceutical Inc.
New York, New York--(Newsfile Corp. - November 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021.
If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
Allegations against BMRN include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you suffered a loss in BioMarin you have until December 22, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103209